Rigel Pharmaceuticals Inc (RIGL) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Rigel Pharmaceuticals reported revenue of $294.3M, up 64.1% from $179.3M the year before. Net income was $367.0M (a 124.7% net margin), or $19.48 per diluted share. Gross margin was 93.3% and operating margin was 42.6%. Operating activities generated $75.7M of cash. At fiscal year end, Rigel Pharmaceuticals held $513.6M in total assets against $122.1M in total liabilities, including $40.6M of cash and equivalents.
Open the full interactive Rigel Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Rigel Pharmaceuticals Key Stats
| Share Price | $47.14 |
|---|---|
| Market Cap | $922.5M |
| P/E Ratio | 2.4 |
| Revenue YoY Growth | +64.1% |
| 52-Week Range | $25.44 – $50.96 |
| Shares Outstanding | 18.5 million (basic, 2026 Q2) |
Rigel Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $108.6M | $149.2M | $120.2M | $116.9M | $179.3M | $294.3M |
| Cost of Goods Sold | $895,000 | $1.1M | $1.7M | $7.1M | $18.6M | $19.6M |
| Gross Profit | $107.7M | $148.2M | $118.5M | $109.8M | $160.6M | $274.7M |
| Operating Income | -$29.0M | -$12.5M | -$55.5M | -$20.5M | $24.2M | $125.5M |
| Pre-Tax Income | -$29.7M | -$17.3M | -$58.6M | -$25.1M | $18.4M | $121.8M |
| Income Tax | — | $605,000 | — | — | $881,000 | -$245.2M |
| Net Income | -$29.7M | -$17.9M | -$58.6M | -$25.1M | $17.5M | $367.0M |
| Diluted EPS | -$1.80 | -$1.10 | -$3.40 | -$1.40 | $0.99 | $19.48 |
Rigel Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $69.5M | $69.8M | $58.8M | $78.7M |
| Net Income | $27.9M | $268.1M | $8.7M | $17.3M |
| Diluted EPS | $1.46 | $14.23 | $0.44 | $0.88 |
Rigel Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $30.4M | $18.9M | $24.5M | $32.8M | $56.7M | $40.6M |
| Current Assets | $89.0M | $154.5M | $115.9M | $99.3M | $135.1M | $240.2M |
| Total Assets | $110.4M | $167.3M | $134.3M | $117.2M | $164.0M | $513.6M |
| Current Liabilities | $40.8M | $63.6M | $65.2M | $53.3M | $63.3M | $99.2M |
| Total Long-Term Debt | $20.0M | $20.0M | $40.0M | $60.0M | $60.0M | $52.5M |
| Total Liabilities | $76.4M | $137.0M | $147.9M | $145.9M | $160.7M | $122.1M |
| Shareholders' Equity | $34.0M | $30.4M | -$13.6M | -$28.6M | $3.3M | $391.5M |
Rigel Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$52.2M | $5.9M | -$73.8M | -$5.7M | $31.5M | $75.7M |
| Cash From Investing | $47.5M | -$80.0M | $72.8M | -$4.3M | $4.1M | -$92.4M |
| Cash From Financing | $12.6M | $62.7M | $6.5M | $18.4M | -$11.6M | $601,000 |
| Free Cash Flow | -$53.4M | $5.3M | -$74.2M | -$6.2M | — | — |
Figures from Rigel Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Rigel Pharmaceuticals financials page for every line item.
Rigel Pharmaceuticals Company Profile
| Ticker | RIGL |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | South San Francisco, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Accelerated filer |
| SEC CIK | 0001034842 |
Frequently Asked Questions
What was Rigel Pharmaceuticals' revenue in fiscal 2025?
Rigel Pharmaceuticals (RIGL) reported revenue of $294.3M for fiscal 2025.
What is Rigel Pharmaceuticals' annual revenue history?
Rigel Pharmaceuticals' annual revenue by fiscal year: 2020: $108.6M; 2021: $149.2M; 2022: $120.2M; 2023: $116.9M; 2024: $179.3M; 2025: $294.3M.
What was Rigel Pharmaceuticals' net income in fiscal 2025?
Rigel Pharmaceuticals reported net income of $367.0M for fiscal 2025.
What was Rigel Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Rigel Pharmaceuticals' diluted EPS was $19.48 for fiscal 2025 (adjusted for any later stock splits).
What was Rigel Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Rigel Pharmaceuticals reported revenue of $78.7M.
How much debt does Rigel Pharmaceuticals have?
Rigel Pharmaceuticals reported $52.5M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Rigel Pharmaceuticals are outstanding?
Rigel Pharmaceuticals reported a weighted average of 18.5 million basic shares outstanding in 2026 Q2.
What is Rigel Pharmaceuticals' market cap?
Based on its latest closing price, Rigel Pharmaceuticals (RIGL) has a market capitalization of about $922.5M.
When does Rigel Pharmaceuticals' fiscal year end?
Rigel Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Rigel Pharmaceuticals headquartered?
Rigel Pharmaceuticals lists its business address in South San Francisco, California in its SEC filings.